1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities.

          Methods

          We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox’s regression, stratified by city and year of diagnosis.

          Results

          During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7–11.8), 6.4 (95% CI, 4.2–9.8), 2.8 (95% 2.1–3.8), 2.0 (95% CI, 1.3–2.8) and 2.3 (95% CI, 1.7–3.0), respectively.

          Conclusion

          We found that half of Colombia’s children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

          In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The 2007 WHO Classification of Tumours of the Central Nervous System

            The fourth edition of the World Health Organization (WHO) classification of tumours of the central nervous system, published in 2007, lists several new entities, including angiocentric glioma, papillary glioneuronal tumour, rosette-forming glioneuronal tumour of the fourth ventricle, papillary tumour of the pineal region, pituicytoma and spindle cell oncocytoma of the adenohypophysis. Histological variants were added if there was evidence of a different age distribution, location, genetic profile or clinical behaviour; these included pilomyxoid astrocytoma, anaplastic medulloblastoma and medulloblastoma with extensive nodularity. The WHO grading scheme and the sections on genetic profiles were updated and the rhabdoid tumour predisposition syndrome was added to the list of familial tumour syndromes typically involving the nervous system. As in the previous, 2000 edition of the WHO ‘Blue Book’, the classification is accompanied by a concise commentary on clinico-pathological characteristics of each tumour type. The 2007 WHO classification is based on the consensus of an international Working Group of 25 pathologists and geneticists, as well as contributions from more than 70 international experts overall, and is presented as the standard for the definition of brain tumours to the clinical oncology and cancer research communities world-wide.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              International incidence of childhood cancer, 2001–10: a population-based registry study

              Summary Background Cancer is a major cause of death in children worldwide, and the recorded incidence tends to increase with time. Internationally comparable data on childhood cancer incidence in the past two decades are scarce. This study aimed to provide internationally comparable local data on the incidence of childhood cancer to promote research of causes and implementation of childhood cancer control. Methods This population-based registry study, devised by the International Agency for Research on Cancer in collaboration with the International Association of Cancer Registries, collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 years in populations covered by high-quality cancer registries with complete data for 2001–10. Incidence rates per million person-years for the 0–14 years and 0–19 years age groups were age-adjusted using the world standard population to provide age-standardised incidence rates (WSRs), using the age-specific incidence rates (ASR) for individual age groups (0–4 years, 5–9 years, 10–14 years, and 15–19 years). All rates were reported for 19 geographical areas or ethnicities by sex, age group, and cancer type. The regional WSRs for children aged 0–14 years were compared with comparable data obtained in the 1980s. Findings Of 532 invited cancer registries, 153 registries from 62 countries, departments, and territories met quality standards, and contributed data for the entire decade of 2001–10. 385 509 incident cases in children aged 0–19 years occurring in 2·64 billion person-years were included. The overall WSR was 140·6 per million person-years in children aged 0–14 years (based on 284 649 cases), and the most common cancers were leukaemia (WSR 46·4), followed by CNS tumours (WSR 28·2), and lymphomas (WSR 15·2). In children aged 15–19 years (based on 100 860 cases), the ASR was 185·3 per million person-years, the most common being lymphomas (ASR 41·8) and the group of epithelial tumours and melanoma (ASR 39·5). Incidence varied considerably between and within the described regions, and by cancer type, sex, age, and racial and ethnic group. Since the 1980s, the global WSR of registered cancers in children aged 0–14 years has increased from 124·0 (95% CI 123·3–124·7) to 140·6 (140·1–141·1) per million person-years. Interpretation This unique global source of childhood cancer incidence will be used for aetiological research and to inform public health policy, potentially contributing towards attaining several targets of the Sustainable Development Goals. The observed geographical, racial and ethnic, age, sex, and temporal variations require constant monitoring and research. Funding International Agency for Research on Cancer and the Union for International Cancer Control.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/1914232Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role:
                Role: Role: Role: Role: Role: Role:
                Role: Role: Role:
                Role:
                Role:
                Role:
                Role:
                Role: Role: Role:
                Role:
                Role:
                Role:
                Role:
                Role:
                Role:
                Role:
                URI : https://loop.frontiersin.org/people/2556074Role:
                URI : https://loop.frontiersin.org/people/1801234Role: Role: Role: Role: Role:
                URI : https://loop.frontiersin.org/people/222128Role: Role: Role:
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                27 February 2024
                2023
                : 13
                : 1326788
                Affiliations
                [1] 1 Unidad de Investigación, Fundación Pediatras Oncólogos y Hematólogos (POHEMA) , Cali, Colombia
                [2] 2 Unidad de Oncología y Hematología Pediátrica, Clínica Imbanaco – Grupo Quirón Salud , Cali, Colombia
                [3] 3 Registro Poblacional de Cáncer de Cali – Departamento de Patología, Universidad del Valle , Cali, Colombia
                [4] 4 Escuela de Enfermería, Universidad del Valle , Cali, Colombia
                [5] 5 Unidad de Oncología y Hematología Pediátrica, Hospital de la Misericordia (HOMI) Fundación Hospital Pediátrico la Misericordia , Bogotá, Colombia
                [6] 6 Grupo de Oncología y Hematología Pediátrica Universidad Nacional de Colombia , Bogotá, Colombia
                [7] 7 Unidad de Oncología y Hematología Pediátrica, Instituto Nacional de Cancerología , Bogotá, Colombia
                [8] 8 Departamento de Pediatría, Universidad del Valle , Cali, Colombia
                [9] 9 Unidad de Oncología y Hematología Pediátrica, Fundación Valle del Lili , Cali, Colombia
                [10] 10 Departamento de Pediatría, Universidad de Cartagena, Unidad de Oncología y Hematología Pediátrica, Clínica Blas de Lezo , Cartagena, Colombia
                [11] 11 Unidad de Oncología y Hematología Pediátrica, Clínica Materno Infantil San Luis , Bucaramanga, Colombia
                [12] 12 Unidad de Oncología y Hematología Pediátrica: Instituto Médico de Alta Tecnología (IMAT) Oncomédica , Montería, Colombia
                [13] 13 Unidad de Oncología y Hematología Pediátrica, Hospital Infantil Los Ángeles , Pasto, Colombia
                [14] 14 Unidad de Oncología y Hematología Pediátrica, Fundación San Vicente de Paul , Medellín, Colombia
                [15] 15 Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California, San Diego , San Diego, CA, United States
                [16] 16 Pediatric Hematology/Oncology, Rady Children’s Hospital San Diego , San Diego, CA, United States
                [17] 17 Population Sciences, Disparities and Community Engagement, Moores Cancer Center, University of California, San Diego , San Diego, CA, United States
                [18] 18 Dissemination and Implementation Science Center, Altman Clinical and Translational Research Institute, University of California, San Diego , San Diego, CA, United States
                Author notes

                Edited by: Diana Osorio, ICON plc, United States

                Reviewed by: Daniel Moreira, St. Jude Children's Research Hospital, United States

                Florencia Moreno, Instituto Nacional del Cancer Argentina, Argentina

                *Correspondence: Oscar Ramirez, oramirez@ 123456pohema.org
                Article
                10.3389/fonc.2023.1326788
                10949889
                38505512
                b3833aec-1d80-48a1-a24e-1542802bfc49
                Copyright © 2024 Ramirez, Piedrahita, Ardila, Pardo, Cabrera-Bernal, Lopera, Suarez, Portilla, Narváez, Rodriguez, Castro, Castro, Estupinan-Perico, Valencia, Álvarez, Fox, Bravo and Aristizabal

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 23 October 2023
                : 12 December 2023
                Page count
                Figures: 4, Tables: 5, Equations: 0, References: 42, Pages: 13, Words: 6580
                Funding
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was partially supported by the “My Child Matters” program of Foundation S (formerly Sanofi-Espoir Foundation; Grants 2009, 2010, 2011, 2012-2015, 2016-2018), Fundación POHEMA (annual grant from 2010 to 2023), the Asociación Colombiana de Hematología Oncología Pediátrica-ACHOP- (annual grant from 2018-2023), and Keira Grace Foundation (annual grant from 2021-2023) who sponsor VIGICANCER. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Categories
                Oncology
                Original Research
                Custom metadata
                Cancer Epidemiology and Prevention

                Oncology & Radiotherapy
                central nervous system neoplasms,pediatrics,treatment outcome,prognosis,epidemiology,latin america,survival,children

                Comments

                Comment on this article